1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Issue 9 (September 2022) Authors: Turkova, Anna; Waalewijn, Hylke; Chan, Man K; Bollen, Pauline D J; Bwakura-Dangarembizi, Mutsa F; Kekitiinwa, Adeodata R; Cotton, Mark F; Lugemwa, Abbas; Variava, Ebrahim; Ahimbisibwe, Grace Miriam; Srirompotong, Ussanee; Mumbiro, Vivian; Amuge, Pauline; Zuidewind, Peter; Ali, Shabinah; Kityo, Ci... Journal: Lancet Issue: Volume 9:Issue 9(2022) Page Start: e627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Issue 9 (September 2022) Authors: Amuge, Pauline; Lugemwa, Abbas; Wynne, Ben; Mujuru, Hilda A; Violari, Avy; Kityo, Cissy M; Archary, Moherndran; Variava, Ebrahim; White, Ellen; Turner, Rebecca M; Shakeshaft, Clare; Ali, Shabinah; Nathoo, Kusum J; Atwine, Lorna; Liberty, Afaaf; Bbuye, Dickson; Kaudha, Elizabeth; Mngqibisa, Rosie;... Journal: Lancet Issue: Volume 9:Issue 9(2022) Page Start: e638 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Issue 2 (February 2021) Authors: Baeten, Jared M; Palanee-Phillips, Thesla; Mgodi, Nyaradzo M; Mayo, Ashley J; Szydlo, Daniel W; Ramjee, Gita; Gati Mirembe, Brenda; Mhlanga, Felix; Hunidzarira, Portia; Mansoor, Leila E; Siva, Samantha; Govender, Vaneshree; Makanani, Bonus; Naidoo, Logashvari; Singh, Nishanta; Nair, Gonasagrie; C... Journal: Lancet Issue: Volume 8:Issue 2(2021) Page Start: e87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗